Investigational drug · Phase 2
MVA-BN
Also called: Quail
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Monkeypox (Mpox).
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
81
Any phase or sponsor naming "MVA-BN"
First trial start
2024
Oct 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MVA-BN", any sponsor or status.
Conditions studied
As listed on its trial records.
- Monkeypox (Mpox)
Largest trials
Live from ClinicalTrials.gov: studies naming "MVA-BN" as an intervention, largest first.
- Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04152486 · 20,426 participants · Start Nov 14, 2019 · Primary completion Jan 31, 2022
Drug: Ad26.ZEBOV, MVA-BN-Filo vaccine · For: Ebola Virus Disease
Sites: Kinshasa, Democratic Republic of the Congo
- MVA-BN-RSV Vaccine TrialPivotal-lookingTerminated
Bavarian NordicIndustry
NCT05238025 · 20,419 participants · Start Apr 19, 2022 · Primary completion Jun 29, 2023
Drug: MVA-BN-RSV vaccine; Tris Buffered Saline (TBS) · For: Respiratory Syncytial Virus Infections
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 120 sites in all
- Partnership for Research on Ebola VACcinationsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02876328 · 4,789 participants · Start Mar 27, 2017 · Primary completion Dec 24, 2019
Drug: Ad26.ZEBOV; MVA-BN-Filo and 3 more · For: Ebola Virus Disease
Sites: Conakry, Guinea; Monrovia, Liberia; Bamako, Mali · 6 sites in all
- A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT04556526 · 4,031 participants · Start Oct 5, 2020 · Primary completion Mar 2, 2023
Drug: Ad26.ZEBOV; MVA-BN-Filo · For: Healthy
Sites: Cuangugu, Rwanda; Gysenyi, Rwanda; Kigali, Rwanda
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsPivotal-lookingCompleted
Bavarian NordicIndustry
NCT01144637 · 4,005 participants · Start Feb 2013 · Primary completion Nov 2013
Drug: IMVAMUNE® · For: Smallpox
Sites: Birmingham, Alabama; Anaheim, California; Los Angeles, California · 34 sites in all
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT02977715 · 1,600 participants · Start Feb 23, 2017 · Primary completion Oct 31, 2025
Drug: JYNNEOS (Liquid Formulation); JYNNEOS (Lyophilized Formulation) · For: Monkeypox Virus Infection
Sites: Boende, Democratic Republic of the Congo
- Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialPivotal-lookingCompleted
Bavarian NordicIndustry
NCT03699124 · 1,129 participants · Start Jun 19, 2019 · Primary completion Jan 6, 2020
Drug: FD MVA-BN · For: Smallpox
Sites: Birmingham, Alabama; Melbourne, Florida; Peoria, Illinois · 12 sites in all
- Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) AdultsPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT02564523 · 1,075 participants · Start Nov 6, 2015 · Primary completion Feb 12, 2019
Drug: Ad26.ZEBOV; MVA-BN-Filo and 1 more · For: Hemorrhagic Fever, Ebola
Sites: BoboDioulasso, Burkina Faso; Ouagadougou, Burkina Faso; Abidjan, Côte d’Ivoire · 7 sites in all
- Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT02509494 · 1,023 participants · Start Sep 30, 2015 · Primary completion Jun 28, 2019
Drug: Ad26.ZEBOV; MVA-BN-Filo and 2 more · For: Ebola Virus Disease
Sites: Freetown, Sierra Leone
- A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT04228783 · 974 participants · Start Feb 18, 2020 · Primary completion Apr 25, 2022
Drug: Ad26.ZEBOV; MVA-BN-Filo and 1 more · For: Ebola
Sites: Mobile, Alabama; Tempe, Arizona; Lexington, Kentucky · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Embryonic estrogens induce hypothalamic progesterone receptor expression to support brain feminization in birds.
Sakiyama A, Masuchi K, Suzuki T, et al. · iScience 2026
- Northern bobwhite quail (Colinus virginianus): Emerging helminth disease, weight of evidence, and pharmaceutical intervention.
Arlowe TB, Suber HN, Leach J, et al. · Int J Parasitol Parasites Wildl 2026
- Dioxin-like contaminants (PCDD/Fs, PBDD/Fs, PXDD/Fs, PCBs, PCNs) & PBDEs in edible avian eggs other than chickens.
Fernandes AR, Rose M, Smith F, et al. · Environ Res 2026
- LC-MS/MS quantification of egg allergens across eight avian species in foods: development, validation, and application.
Xu Y, Chen R, Shencheng Y, et al. · Food Chem 2026
- Effects of polystyrene microplastics and nanoplastics on the hypothalamic-pituitary-testicular axis of Japanese quail.
Pei X, Yang J, Qiao H, et al. · Theriogenology 2026
- Mpox vaccination in Belgium: clinical guidance for implementation readiness.
Callens S, Blot K, De Scheerder MA, et al. · Acta Clin Belg 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.